01
Jul

You can score another setback for Roche’s star-crossed attempt to develop a new drug for Alzheimer’s. Roche partner Evotec reported that their drug sembragiline failed a Phase IIB study.

…read more

Source: Roche forced to concede another flop for Alzheimer’s program

    

0 No comments